LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation

    Expands U.S. Clinical Development Operations With Appointment of Senior
    Director of Medical and Clinical Research and Director of Medical Affairs

    HORSHOLM, Denmark, June 21 /CNW/ - Summary: LifeCycle Pharma has
established a Scientific Advisory Board for its transplantation programs. In
addition, LifeCycle Pharma announces the expansion of its United States (U.S.)
clinical development department with the addition of Drs. Rob Gordon and Larry
    LifeCycle Pharma A/S (OMX:LCP) today announced the formation of an
international Scientific Advisory Board (SAB) of experts in the field of organ
transplantation. The SAB will provide counsel to the company's management team
as LifeCycle Pharma expands its development programs within the area of solid
organ transplantation.

    The SAB consists of six internationally recognized thought leaders from
the U.S. and Europe, including:

    -   Dr. Rita R. Alloway, Director of Transplant Clinical Research,
        University of Cincinnati

    -   Dr. Klemens Budde, Medical Director of Transplantation, Charite
        University Hospital, Berlin

    -   Dr. Robert S. Gaston, Medical Director of Kidney & Pancreas
        Transplantation, University of Alabama, Birmingham

    -   Dr. Josep M. Grinyo, Chief, Division of Nephrology, University
        Hospital of Bellvitge, Barcelona

    -   Dr. John R. Lake, Director, Gastroenterology Division, University of
        Minnesota, Minneapolis

    -   Dr. Marc D. Pescovitz, Professor of Surgery and
        Microbiology/Immunology, Indiana University Medical Center,

    "As LifeCycle Pharma advances its product portfolio within organ
transplantation, the Scientific Advisory Board will provide an instrumental
role in guiding our research and development programs," said Dr. Flemming
Ornskov, President and CEO of LifeCycle. "We have attracted established, and
highly respected members of the transplantation field who will play a pivotal
role in LifeCycle Pharma bringing innovation to this disease area," added Dr.
    In addition, LifeCycle Pharma has strengthened its clinical development
capabilities in the U.S. with the addition of Drs. Robert Gordon, as Senior
Director of Medical and Clinical Research, and Larry Chodoff, as Director of
Medical Affairs Transplantation.
    Dr. Gordon is an internationally respected transplant surgeon who has
spent more then 30 years in academia and industry. He was a member of the team
that was headed by the world renowned transplant surgeon, Dr. Thomas Starzl,
at the University of Colorado and the University of Pittsburgh. From 1992
until he moved to industry, Dr. Gordon was Professor of Surgery and Director
of the Liver Transplant Service at Emory University Hospital in Atlanta,
Georgia. Most recently, Dr. Gordon was the Senior Medical Director for
Transplantation at Roche Laboratories in Nutley, New Jersey.
    After 17 years of practice at the Mount Sinai Medical Center in New York,
New York, Dr. Larry Chodoff joined Novartis Pharmaceuticals Corporation in
1997, as Associate Director of Clinical Research, managing global research and
development programs in organ transplantation and autoimmune diseases. Prior
to joining LifeCycle Pharma, Dr. Chodoff held the position of Medical Liaison
in Transplantation and Immunology at Roche Laboratories. Dr. Chodoff received
his Pharm.D. from the University of the Pacific School of Pharmacy in 1979.
    "Their combined experience of more than 50 years of working within the
area of organ transplantation will be a great asset for LifeCycle Pharma as
our LCP-Tacro program enters Phase II clinical trials," said Dr. Michael
Beckert, Chief Medical Officer at LifeCycle Pharma, who will oversee the
responsibilities of Drs. Rob Gordon and Larry Chodoff.

    About LCP-Tacro:

    Tacrolimus is a leading immunosuppressive medication to prevent rejection
after organ transplantation. LCP-Tacro is being developed as a once-daily
tablet version of tacrolimus, with improved bioavailability and reduced
variability; compared to both Astellas' twice daily version of tacrolimus
(Prograf(R)), and its modified-release version of tacrolimus for organ
transplants. This is expected to represent significant improvements for
    Transplant patients need to maintain a minimum level of tacrolimus in the
blood to prevent organ rejection, but too high levels increase the risk of
serious side effects such as, kidney damage or hypertension. Therefore,
tacrolimus levels need to be managed carefully. Transplant patients are
typically obliged to make frequent visits to the hospital for monitoring and
dose adjustments for months after receiving a new organ. Management of the
tacrolimus levels is complicated by the low bioavailability of Prograf(R), its
variable absorption, and its interaction with food and other drugs.

    About LifeCycle Pharma A/S:

    LifeCycle Pharma, headquartered in Horsholm, Denmark, is an emerging
pharmaceutical company with a broad and late stage product pipeline in
therapeutic areas of cholesterol management, hypertension, organ transplant
and autoimmune diseases. LifeCycle Pharma's proprietary technology platform,
MeltDose(R) technology, offers lower dosing, reduced side effects and improved
safety and patient compliance, as well as reduced product development time and
development costs. LifeCycle Pharma is listed on the OMX Nordic Exchange under
the trading symbol (LCP). Please visit for further
information about LifeCycle Pharma A/S.

For further information:

For further information: LifeCycle Pharma A/S, Michael Wolff Jensen,
Executive Vice President and CFO, Tel. +45-40-74-62-44

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890